secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001641172-25-013823
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics changes auditor to Baker Tilly after Moss Adams merger
---------------------------------------------------------------------------

- Moss Adams merged into Baker Tilly US, LLP effective June 3, 2025; audit committee approved Baker Tilly as successor.
- No disagreements with Moss Adams on accounting principles or audit scope for FY2024, FY2023, or interim period.
- Prior audit reports included a going concern uncertainty paragraph; no adverse or modified opinions.
- Moss Adams provided a letter agreeing with the statements, filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225013823/0001641172-25-013823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225013823/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer